Yuichi Yoshida, Mio Fujiwara, Mizuki Kinoshita, Kentaro Sada, Shotaro Miyamoto, Yoshinori Ozeki, Miyuki Iwamoto, Yumi Mori, Satoshi Nagai, Naoki Matsuda, Takaaki Noguchi, Mitsuhiro Okamoto, Koro Gotoh, Takayuki Masaki, Hirotaka Shibata
Primary aldosteronism (PA) is typically managed with mineralocorticoid receptor antagonists (MRAs) barring adrenalectomy. The efficacy of esaxerenone, a nonsteroidal MRA, were explored in patients with PA. Various parameters such as the urinary albumin to creatinine ratio (UACR) and serum levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) were evaluated in 25 PA patients before and 3 and 6 months after esaxerenone treatment. Systolic and diastolic blood pressure (BP), and the estimated glomerular filtration rate decreased after treatment, while serum levels of potassium and active renin increased...
September 17, 2023: Hypertension Research: Official Journal of the Japanese Society of Hypertension